Tumor Mutational Burden Testing in Solid Tumors-Reference-Cited by-同舟云学术

Tumor Mutational Burden Testing in Solid Tumors

Published:2023-12-01 Issue:12 Volume:9 Page:1725
ISSN:2374-2437
Container-title:JAMA Oncology
language:en
Short-container-title:JAMA Oncol

Author:

Kwon Regina¹,Cheng Heather H.²³,Pritchard Colin C.¹⁴⁵

Affiliation:

1. Department of Laboratory Medicine & Pathology, University of Washington, Seattle

2. Division of Medical Oncology, Department of Medicine, University of Washington, Seattle

3. Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington

4. VA Puget Sound Health Care System, Seattle, Washington

5. Brotman Baty Institute for Precision Medicine, Seattle, Washington

Abstract

A 58-year-old man with diabetes, chronic kidney disease, and JAK2-positive myeloproliferative neoplasm is referred for newly diagnosed oligometastatic prostate cancer with substantial urinary symptoms. What would you do next?

Publisher

American Medical Association (AMA)

Subject

Oncology,Cancer Research

Link

https://jamanetwork.com/journals/jamaoncology/articlepdf/2811050/jamaoncology_kwon_2023_dt_230001_1702491847.39492.pdf

Reference8 articles.

1. Tumor mutational burden and response rate to PD-1 inhibition.;Yarchoan;N Engl J Med,2017

2. Tumor mutational burden as a predictor of immunotherapy response: is more always better?;Strickler;Clin Cancer Res,2021

3. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden.;Chalmers;Genome Med,2017

4. Whole-genome sequencing reveals elevated tumor mutational burden and initiating driver mutations in African men with treatment-naïve, high-risk prostate cancer.;Jaratlerdsiri;Cancer Res,2018

5. Disparities in tumor mutational burden, immunotherapy use, and outcomes based on genomic ancestry in non-small-cell lung cancer.;Brawley;JCO Glob Oncol,2021